Creating a Soluble Binder to Endothelin-1 Based on the Natural Ligand Binding Domains of the Endothelin-1 (G-Protein-Coupled) Receptor
- 104 Downloads
Since its discovery in 1989, there has been extensive research on endothelin (ET)-1 physiology, as well as pathology. Accordingly, there is considerable research on the discovery of therapeutics based around ET-1, amongst which current treatment options include endothelin receptor antagonists. These target the ET-1 receptors, which are G-protein–coupled receptors (GPCRs). We have effectively developed a soluble form of a GPCR that binds to ligands, by constructing a fusion polypeptide of different endothelin receptor ligand binding domains. Phage experiments identified strong binders to ET-1. We then constructed Fc-fusions of the top binders and further binding assays revealed a KD of 21.2 nM for the Fc-ETtr1 construct and KD of 77.3 nM for the Fc-ETtr2 construct. These constructs are soluble and have the ability to bind and potentially sequester elevated ET-1 levels that are prevalent in different diseases. These results provide a novel approach to targeting GPCR–binding ligands, and thereby to contribute to a very important class of therapeutics.
KeywordsECL ETA receptor ETB receptor Endothelin-1 traps FFP (Fc-fusion proteins) GPCR (G-protein-coupled receptors)
Epitope human influenza hemagglutinin epitope
Ligand binding domain
Phosphate buffered saline tween
Super broth medium
We would like to thank DM; Ms. Leela Jain for all her support. We also thank RC for funding this project.
AJ and VM participated in the research design. AJ, VM and HY conducted the experiments. AJ, KH, AJ and IJ contributed new reagents or analytic tools. VM and AJ performed the data analysis. AJ, VM, KH, AJ, MJ and IJ wrote or contributed to the writing of the manuscript.
This project was funded by private funding.
Compliance with Ethical Standards
Conflict of interest
The author(s) declare that they have no competing interests.
- Gabbay E, Fraser J, McNeil K (2007) Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 3(6):887–900Google Scholar